Newsfeeds - Spark Newswire

1 minute read

Reported Late Wednesday March 08, Curis Reschedules Q4 2022 Business Update And Conference Call To Monday, March 13, 2023 At 8:30 a.m. ET

Today, 4:00 PM

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter business

CRIS

1 minute read

Earnings

Earnings Preview For Curis

By Benzinga Insights

Today, 4:00 PM

Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Thursday, 2023-03-09. Here’s what investors need…

CRIS

18 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 4:00 PM

Thursday's session saw 329 companies set new 52-week lows.

ABNB

5 minute read

Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 4:00 PM

Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.

ACMR

5 minute read

Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 4:00 PM

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.

ACET

1 minute read

Curis Announces Additional Clinical Data From TakeAim Leukemia Study Of emavusertib In Monotherapy R/R AML And hrMDS

By Benzinga Newsdesk

Today, 4:00 PM

29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutation 45% ORR observed in R/R hrMDS patients with spliceosome mutation Curis to review

CRIS

1 minute read

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $9

By Benzinga Newsdesk

Today, 4:00 PM

HC Wainwright & Co. analyst Edward White maintains Curis (NASDAQ:CRIS) with a Buy and lowers the price target from $16 to $9.

CRIS

1 minute read

Earnings

Earnings Outlook For Curis

By Benzinga Insights

Today, 4:00 PM

Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Curis will report an earnings per share (EPS) of $-0.17.

CRIS